The forkhead transcription factor FOXO1, a downstream target of phosphatidylinositol-3-kinase/Akt signalling pathway, regulates cyclic differentiation and apoptosis in normal endometrium, but its role in endometrial carcinogenesis is unknown. Screening of endometrial cancer cell lines demonstrated that FOXO1 is expressed in HEC-1B cells, but not in Ishikawa cells, which in turn highly express the FOXO1 targeting E3-ubiquitin ligase Skp2. FOXO1 transcript levels were also lower in Ishikawa cells and treatment with the proteasomal inhibitor was insufficient to restore expression. Lack of FOXO1 expression in Ishikawa cells was not accounted for by differential promoter methylation or activity, but correlated with increased messenger RNA (mRNA) turnover. Comparative analysis demonstrated that HEC-1B cells proliferate slower, but are more resistant to paclitaxel-mediated cell death than Ishikawa cells, which were partially reversed upon silencing of FOXO1 in HEC-1B cells or its re-expression in Ishikawa cells. We further show that FOXO1 is required for the expression of the growth arrest-and DNA-damageinducible gene GADD45a. Analysis of biopsy samples demonstrated a marked loss of FOXO1 and GADD45a mRNA and protein expression in endometrioid endometrial cancer compared to normal endometrium. Together, these observations suggest that loss of FOXO1 perturbs endometrial homeostasis, promotes uncontrolled cell proliferation and increases susceptibility to genotoxic insults.
Introduction
Endometrial cancer is the most common malignancy of the female reproductive tract and its incidence is on the increase in North America and Europe (Amant et al., 2005; Shang, 2006) . Endometrial carcinomas are divided into two groups; endometrioid (type I) and nonendometrioid (type II) endometrial cancers. The common type I tumours, which account for 80% of all endometrial carcinomas, are oestrogen-related, lowgrade, affect pre-and perimenopausal women, and are often preceded by complex atypical endometrial hyperplasia. In contrast, type II tumours are not oestrogendriven and mostly develop in atrophic endometrium. Loss or mutation of the tumour-suppressor gene PTEN is the earliest detectable genetic defect in type I endometrioid endometrial cancer (EEC) (Kong et al., 1997) . PTEN encodes a lipid phosphatase that specifically dephosphorylates the D3 position of phosphatidylinositol 3,4,5-triphosphate, and thereby, functionally antagonizes the phosphatidylinositol-3-kinase/Akt (PI3K/ Akt) signalling pathway. Consequently, loss of PTEN function results in constitutive activation of the PI3K/ Akt signal transduction pathway, a hallmark of many cancers (Cully et al., 2006) .
The FOXO subfamily of Forkhead transcription factors is a direct downstream target of the PI3K/Akt pathway (Brunet et al., 1999; Kops et al., 1999) . This family comprises of three functionally related members, FOXO1, FOXO3a and FOXO4. FOXO proteins are evolutionarily conserved transcriptional activators of genes involved in cell cycle inhibition (for example, p27 kip ) (Dijkers et al., 2000) , apoptosis (for example, BIM, FAS ligand and TRAIL) (Sunters et al., 2003) , defence against oxidative stress (for example, manganese superoxide dismutase (MnSOD) and catalase), and DNA repair (for example, growth arrest-and DNA damageinducible protein a of 45 kDa (GADD45a)) (Kops et al., 2002; Nemoto et al., 2004) . PI3K/Akt-dependent phosphorylation of FOXO proteins triggers their export from the nucleus in a CRM1 transporter-dependent manner and promotes binding of these transcription factors to the 14-3-3 chaperone proteins in the cytosol. PI3K/Akt signalling further antagonizes FOXO-dependent transcription by earmarking the phosphorylated proteins for proteosomal degradation (Plas and Thompson, 2003) . In addition to Akt, other kinases, such as SGK1 (serum-and glucocorticoid-inducible kinase 1), CK1 (casein kinase 1) and DYRK1A (dual-specificity tyrosine-phosphorylated and regulated 1A), have also been implicated in FOXO phosphorylation and nuclear export (Brunet et al., 2001; Woods et al., 2001; Rena et al., 2002) .
FOXO1 expression in human endometrium increases during the secretory phase of the cycle. In contrast, FOXO3a is repressed in differentiating endometrium and FOXO4 appears not to be expressed in this tissue, at least not at protein level (Labied et al., 2006) . Recently, we demonstrated that FOXO1 plays a major role in endometrial homeostasis by regulating cyclic differentiation (decidualization) and apoptosis of stromal cells in response to the rise and fall in ovarian progesterone levels . FOXO 1 is also abundantly expressed in endometrial epithelial cells, but its function in this cellular compartment is as yet unknown. In this study, we demonstrate that FOXO1 serves as a tumour suppressor in endometrial cancer cells, involved in normal growth control and maintenance of genomic stability.
Results

Differential expression of FOXO1 in endometrial carcinoma cell lines
We hypothesized that inactivation of FOXO transcription factors could constitute a molecular link between dysregulation of the PTEN/PI3K/Akt signal cascade and endometrial tumorigenicity. To examine the role of FOXO1 in endometrial cancer, we first screened a panel of cell lines. Western blot analysis showed that FOXO1 is expressed in HEC-1B, HEC1A cells, but not in HEC-50B, HEC-108 and Ishikawa cells (data not shown). HEC-1B and Ishikawa cells are widely used for the study of endometrial cancer and chosen for further analysis. Although both cell lines are deficient in PTEN expression, PI3K/Akt activity was considerably higher in Ishikawa cells, as reflected by the phosphorylated Akt levels ( Figure 1a ). In addition, Ishikawa cells also express higher levels of Skp2, an oncogenic subunit of the Skp1/Cul1/F-box protein ubiquitin complex that promotes ubiquitination and degradation of phosphorylated FOXO1 (Huang et al., 2005) . These observations indicated that lack of detectable FOXO1 levels in Ishikawa cells could be a consequence of constitutive PI3K/Akt-dependent phosphorylation of this transcription factor and proteasomal degradation. However, inhibition of the ubiquitin/proteasome pathway with MG132 resulted in accumulation of FOXO1 in HEC-1B cells, but not in Ishikawa cells (Figure 1b ). This prompted us to examine FOXO1 transcript levels, which were eightfold lower in Ishikawa cells when compared to HEC-1B cells (Figure 1c) . The results suggested that impaired gene expression, rather than targeted phosphorylation and proteasomal degradation, accounts for loss of FOXO1 in Ishikawa cells.
Loss of FOXO1 expression correlates with increased messenger RNA turnover We hypothesized that the low level of FOXO1 messenger RNA (mRNA) expression in Ishikawa cells could reflect epigenetic silencing through hypermethylation of its promoter, a common mechanism of inactivating tumour suppressor genes in cancer. The proximal FOXO1 promoter harbours a CpG-rich region, defined as a stretch of DNA that has both a >50% GC content and an observed overexpected frequency of CpG dinucleotides of >0.6 (Gardiner-Garden and Frommer, 1987) . We first used bisulphite genomic sequencing to determine the methylation status of a 300-bp region of the FOXO1 promoter region (À617 to À317 relative to the transcription start site), which encompasses 29 CpG sites. However, no differences were found in FOXO1 promoter methylation between HEC-1B and Ishikawa cells as determined by bisulphite genomic sequencing ( Figure 2a ). To confirm that the low expression of FOXO1 transcripts in Ishikawa cells was not due to promoter hypermethylation, we treated these cells with the DNA demethylating agent 5-aza-2 0 -deoxycytidine (5-aza-dC) for 24 or 48 h. As expected, real-time quantitative-PCR (RTQ-PCR) showed no difference in FOXO1 mRNA levels between treated and untreated cells ( Figure 2b ). Next, we transfected HEC-1B and Ishikawa cells with the FOXO1 promoter (À1845 to -7) coupled to luciferase and found that basal promoter activity was comparable between these cell lines (Figure 2c ). Together, these data did not support our (Christian et al., 2002) (Figure 3b ). FOXO1 knockdown in HEC-1B cells increased cellular proliferation determined by MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) assay shown in Figure 3c , whereas overexpression of FOXO1(A3) in Ishikawa cells, even at relatively modest levels, inhibited proliferation (Figure 3d ), increasing the doubling-time twofold. Notably, silencing or expression of FOXO1 FOXO1 confers resistance to paclitaxel-induced apoptosis FOXO proteins have been shown to mediate programmed cell death in response to paclitaxel in other cell systems, including breast cancer cells (Sunters et al., 2003 (Sunters et al., , 2006 . To determine whether FOXO1 plays a role in mediating cellular sensitivity to cytotoxic drugs in endometrial cancer cells, we first treated HEC-1B and Ishikawa cells with increasing concentrations of paclitaxel, ranging from 0.1 to 100 nM, for 24 h. As shown in Figure 4a , loss of cell viability was much more pronounced in Ishikawa cells than HEC-1B cells when exposed to paclitaxel at concentrations between 10 and 100 nM. Flow cytometry confirmed that the fraction of dead or dying cells containing o2n DNA was considerably higher in Ishikawa cells than in HEC-1B cells after 24 h of treatment with 10 nM paclitaxel ( Figure 4b ). Interestingly, paclitaxel markedly enhanced FOXO1 promoter activity (Figure 4c 
FOXO1 regulates GADD45a expression
To further explore the loss of FOXO1 in endometrial cancer cells, we examined HEC-1B and Ishikawa cells for the expression of GADD45a, a putative FOXO target gene involved in DNA repair and maintaining genomic stability (Tran et al., 2002) . As shown in Figures 6a and b, GADD45a was readily detectable in HEC-1B, but not in Ishikawa cells by western blot analysis. Transfection of FOXO1 siRNA attenuated GADD45a levels in HEC-1B cells (Figure 6a ), whereas expression of FOXO1(A3) was sufficient to induce its expression in Ishikawa cells (Figure 6b ). Paclitaxel treatment for 24 h enhanced GADD45a levels in HEC-1B cells and induced its expression in Ishikawa cells.
Interestingly, while the response to paclitaxel was inhibited in HEC-1B cells transfected with FOXO1 siRNA, it was independent of FOXO1(A3) expression in 
Loss of FOXO1 and GADD45a expression in EEC
Our in vitro data suggested that loss of FOXO1 expression could be an important event in endometrial carcinogenesis. To test this hypothesis, we first examined the expression of FOXO1 transcripts in 14 normal endometrial samples, taken randomly in the cycle, and in 25 type I EECs by RTQ-PCR. In addition, we examined the expression of transcripts that encode for the other FOXO family members, FOXO3a and FOXO4. As shown in Figure 7a , FOXO3a and FOXO4 mRNA levels did not differ between normal and malignant endometrium. In contrast, FOXO1 transcripts were approximately sixfold less abundant in EEC than in cycling endometrium. To substantiate this finding, we examined FOXO1 immunoreactivity in 15 normal endometrial samples and 35 EECs (Figure 7b ). FOXO1 immunostaining in proliferative endometrium was confined to epithelial cells and its expression in this compartment increased further during the secretory phase of the cycle. In addition, decidualizing stromal cells in secretory endometrium were also strongly FOXO1 immunopositive. FOXO1 was not detectable in 77% (27/35) of EECs (Figure 7b ). In the remaining cases, FOXO1 immunoreactivity was weak and, in contrast to cycling endometrium, often confined to the cytoplasm. To confirm these findings, 31 EEC needle core biopsies were spotted on a tissue microarray (TMA). FOXO1 immunoreactivity was undetectable in 10 out of 13 (77%) grade I EECs, 6 out of 8 (75%) grade II and 8 out of 10 (80%) grade III tumours (data not shown). Together, these data point towards a marked reduction in FOXO1 activity in EEC, which is, at least partially, accounted for by impaired FOXO1 mRNA expression.
To further determine the in vivo relevance of loss of FOXO1 in endometrial cancer cells, we also compared the levels of GADD45a transcripts in normal endometrium and EECs. RTQ-PCR analysis demonstrated a fourfold reduction in GADD45a mRNA expression in cancer samples when compared to normal endometrium (Figure 7c ), paralleling the downregulation of FOXO1 transcripts. This was further validated by immunohistochemistry. Like FOXO1, GADD45a was expressed in FOXO1 and endometrial cancer T Goto et al normal endometrial epithelial cells throughout the cycle, but staining in the stromal compartment was confined to decidualizing cells, during the secretory phase of the cycle (Figure 7d ). GADD45a immunoreactivity was weak or absent in a majority of EECs, especially in cases with lots of necrosis, and the findings confirmed by staining the TMA. Thus, the loss of GADD45a immunoreactivity was comparable, albeit less pronounced, to that of FOXO1 (Figure 7b) .
Finally, we used methylation-specific PCR analysis to examine in vivo the methylation status of the FOXO1 promoter in a limited number of normal endometrial samples and EECs. As shown in Figure 8 , the FOXO1 promoter region was unequivocally unmethylated in the seven endometrial biopsies obtained from normal cycling women. The results of this analysis in EEC were much more heterogeneous, showing partial promoter methylation in five cases, lack of methylation in four cases and complete methylation in a single case.
Discussion
The cyclical waves of proliferation, differentiation, shedding and regeneration of human endometrium, which occur on average 400 times during reproductive life, are unparalleled in any other tissue of the body. Endometrial cancer is the most common malignancy of the female reproductive tract (Amant et al., 2005; Shang, 2006) , yet the molecular safeguards that ensure endometrial homeostasis are poorly understood. FOXO transcription factors have emerged as key mediators of cell fate decisions through their ability to regulate seemingly opposing cellular responses, such as differentiation, apoptosis, cell cycle arrest and defence responses against oxidative and genotoxic stress (Dijkers et al., 2000; Kops et al., 2002; Sunters et al., 2003; Nemoto et al., 2004) . Recent studies in human endometrium have provided further evidence for this ability of FOXO transcription factors to regulate diverse gene programmes in response to changing hormonal and environmental cues Labied et al., 2006) . For example, FOXO1 critically regulates the expression of decidual marker genes, such as PRL and IGFBP-1, in differentiating human endometrial stromal cells in response to elevated progesterone levels, but elicits BIM (BCL2L11) expression, a BH3 domain protein that induces apoptosis of decidualized cells upon progesterone withdrawal.
In contrast to stromal cells, FOXO1 is constitutively expressed in normal endometrial epithelial cells throughout the cycle. Several strands of existing evidence indicated that loss of FOXO1 activity in epithelial cells would be an integral event in neoplastic transformation of endometrium, especially in EECs. First, loss or mutation of the tumour-suppressor gene PTEN is the earliest detectable genetic defect in EECs (Kong et al., 1997) and leads to unrestrained PI3K/Akt signalling, which, in turn, would phosphorylate and inactivate FOXO transcription factors (Brunet et al., 1999; Kops et al., 1999) . Second, Skp2, the oncogenic subunit of the Skp1/Cul1/F-box protein complex that directs FOXO1 ubiquitination and proteasomal degradation, is overexpressed in EECs (Lahav-Baratz et al., 2004) . Third, the expression of known FOXO target genes, such as the cyclin-dependent kinase inhibitor p27 kip , is dramatically lower in malignant endometrium (Bamberger et al., 1999) . Moreover, unopposed oestrogen signalling, a well-recognized risk factor for EEC (Amant et al., 2005; Shang, 2006) , has been shown to enhance PI3K/Akt activity through binding of oestrogen receptor a (ERa) to the p85a regulatory subunit of PI3K . Conversely, recent studies in heterozygote Pten þ /À mice, which develop EECs with full penetrance, demonstrated that enhanced PI3K/Akt signalling leads to targeted phosphorylation of ERa on Ser167 and ligand-independent activation, thus mimicking a hyperestrogenic environment (Vilgelm et al., 2006) . Furthermore, FOXO1 engages in the transcriptional cross-talk with ERa through physical interaction (Schuur et al., 2001) , suggesting an important role for FOXO1 in mediating oestrogen responses in target tissues.
This study shows that FOXO1 activity is indeed lost in EECs. Using relevant cell line models, we demonstrate that FOXO1 not only limits proliferation of endometrial cancer cells, but also that its induction and activation confers resistance to paclitaxel. This appears to be in contrast to breast cancer cells, where paclitaxel treatment results in c-Jun NH2-terminal kinase 1/2-dependent activation of FOXO3a, but not FOXO1, which in turn increases BIM expression and elicits apoptosis (Sunters et al., 2003 (Sunters et al., , 2006 . It is possible that altered sensitivity to paclitaxel mediated by FOXO1 expression is secondary to different cellular growth. Toxicity to anticancer drugs such as paclitaxel involves generation of reactive oxygen species, resulting in indiscriminate damage to proteins, lipids and DNA (Varbiro et al., 2001; Laurent et al., 2005) . Therefore, another mechanism whereby FOXO1 could limit cytotoxity involves induction of free radical scavengers, such as the mitochondrial MnSOD (Kops et al., 2002; Nemoto et al., 2004) , which is indeed the case in endometrial cancer cell lines (data not shown). Other mechanism involves the expression of DNA-repair genes. GADD45a expression is induced in many cell types by cellular stress and various DNA-damaging agents, such as ultraviolet light, ionizing radiation and alkylating agents, and causes G 2 /M cell cycle arrest and DNA repair (Tran et al., 2002; Brunet et al., 2004; Lal et al., 2006) . GADD45 proteins can also trigger apoptosis of cells damaged beyond repair. We have now shown that GADD45a is constitutively expressed in normal endometrial epithelial cells, suggesting that it has an important role safeguarding genomic stability during the cyclical waves of proliferation and shedding. In addition, we demonstrated that basal GADD45a expression in endometrial cells is dependent on FOXO1 activity and, in agreement, a marked reduction in GADD45a levels was observed in ECCs, paralleling the loss of FOXO1 expression. However, transcriptional induction of GADD45a by cytotoxic stress also involves other transcription factors such as p53 and simultaneous de-repression from factors such as c-myc and ZBRK1 (Zheng et al., 2000; Tran et al., 2002) . These alternative mechanisms may explain the induction of GADD45a in paclitaxel-treated Ishikawa cells, which appeared to be independent of FOXO1.
An important observation is that loss of FOXO1 in EECs may not primarily reflect increased PI3K/Akt signalling. Approximately 75% of both low-and highgrade tumours were devoid of FOXO1 staining, indicating that loss of this transcription factor may be an early event in endometrial carcinogenesis. In addition, we found no correlation between FOXO1 and PTEN staining (data not shown), but admittedly a 100 bp ladder 100 bp ladder 100 bp ladder T1  T2  T3  T4   T6  T7  T8  T9  T10   N1  N2  N3  N4  N5  N6  N7 T5 Figure 8 Methylation pattern of the proximal FOXO1 promoter region in normal and malignant endometrial tissues. MSP analysis of 10 frozen EECs demonstrates heterogenicity in FOXO1 promoter methylation. The promoter region was completely methylated in one tumour (T6), unmethylated in four tumours (T3, T5, T7 and T10), and partially methylated in the remaining cases. MSP analysis of the seven frozen normal endometrial biopsies (N1-7) demonstrated lack of FOXO1 promoter methylation in all cases. MSP, methylation-specific PCR; RTQ-PCR, realtime quantitative-PCR.
FOXO1 and endometrial cancer T Goto et al larger clinicopathological study is required to validate these findings, to examine the expression of FOXO1 in hyperplastic endometrial lesions and to assess if lack of FOXO1 correlates with the presence of PTEN mutations. However, we did find a sixfold reduction in FOXO1 transcript levels in neoplastic, when compared to cycling endometrium. This observation concurs with the findings of a recent gene microarray study, demonstrating lower FOXO1 mRNA expression not only in EEC, but also in non-endometrioid cancers when compared to cycling endometrium (Risinger et al., 2003) . However, this study also reported lower FOXO4 transcript levels in EEC, an observation that we were unable to confirm by RTQ-PCR. The mechanism responsible for lack of FOXO1 expression in EEC is not entirely clear. In contrast to normal endometrium, the FOXO1 promoter was methylated in 6 out of 10 EECs, although the degree varied considerably between tumour samples. Thus, our findings suggest that methylation events may not be causal to the loss of FOXO1 expression in EECs, although the results are not conclusive. Comparative analysis of HEC-1B and Ishikawa cells demonstrated that loss of FOXO1 expression did correlate with increased decay of its mRNA. It is interesting to note that microRNAs complementary to FOXO1 have been identified in several species, including humans (http://microrna. sanger.ac.uk/). Furthermore, FOXO1 mRNA has an extended 3 0 -UTR that contains several AUUA pentamers, indicating potential regulation by RNA-binding proteins (Yeap et al., 2002) .
From a clinical perspective, dysregulation of FOXO transcription factors has been described in several other cancers, including breast cancer, prostate cancer and leukaemia (Arden, 2006) . This suggests that they may be useful therapeutic targets and a screen of small molecules has identified several compounds capable of enhancing FOXO1 activity by disabling its nuclear export (Kau et al., 2003) . If our observations in endometrial cell lines are recapitulated in vivo then inhibiting FOXO1 mRNA turnover may be necessary to enhance the efficacy of such compounds in the treatment of EEC.
Materials and methods
Cell culture
Human endometrial cancer cells (HEC-1B and Ishikawa cells) were maintained in Dulbecco's modified Eagle's medium/F12 (GIBCO Industries Inc., Carlsland, CA, USA) supplemented with 10% fetal bovine serum (Hyclone, Logan, UT, USA), 2 mM L-Glutamine and 100 U/ml penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA), in a humidified incubator in an atmosphere of 5% CO 2 at 371C, and routinely tested for mycoplasma infection. Paclitaxel was obtained from Sigma-Aldrich (Poole, UK) and dissolved in dimethyl sulphoxide (DMSO).
Western blot analysis
Whole-cell extracts or nuclear and cytoplasmic protein fractions were immunoblotted as described previously (Brosens et al., 1999; Zoumpoulidou et al., 2004) . Antibodies to FOXO1, phospho-FOXO1 (Ser256), Akt, phospho-Akt (Ser473) (Cell Signaling Technology, Danvers, MA, USA), Skp2 (Invitrogen), GADD45a (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and PARP Cleavage Site (214/215) (Biosource, Carmavillo, CA, USA) were used at 1:1000, whereas the antibody to b-actin (Abcam, Cambridge, UK) was diluted 1:100 000.
Real-time quantitative-PCR Total RNA was isolated from endometrial cancer cell lines and tissue samples, complementary DNA prepared and amplified as described previously (Labied et al., 2006) . The following gene-specific primer pairs were used: L19-sense (5 0 -GCG GAA GGG TAC AGC CAA T-3 0 ) and L19-antisense (5 0 -GCA GCC GGC GCA AA-3 0 ); FOXO1-sense (5 0 -TGG ACA TGC TCA GCA GAC ATC-3 0 ) and FOXO1-antisense (5 0 -TTG GGT CAG GCG GTT CA-3 0 ); FOXO3a-sense (5 0 -CCC AGC CTA ACC AGG GAA GT-3 0 ) and FOXO3a-antisense (5 0 -AGC GCC CTG GGT TTG G-3 0 ); FOXO4-sense (5 0 -CCT GCA CAG CAA GTT CAT CAA-3 0 ) and FOXO4-antisense (5 0 -TTC AGC ATC CAC CAA GAG CTT-3 0 ); GADD45a-sense (5 0 -TCT CGG CTG GAG AGC A-3 0 ) and GADD45a-antisense (5 0 -GGC TTT GCT GAG CAC T-3 0 ). L19, a nonregulated ribosomal housekeeping gene, served as an internal control and was used to normalize for differences in input RNA. All measurements were performed in triplicate.
Bisulphite genomic sequencing and demethylation
The proximal FOXO1 promoter region was first analysed for the presence of CpG islands using the CpG Island Searcher (www.cpgislands. com). Next, genomic DNA was extracted from HEC-1B and Ishikawa cells, using the Dneasy Tissue Kit (Qiagen, Crawley, UK) and modified with sodium bisulphite using the CpGenome DNA Modification Kit (Chemicon, Temecula, CA, USA). PCR amplification of the FOXO1 promoter region (À617 to À317 relative to the transcription start site) was performed using Hot Start Taq Polymerase (Qiagen) with the following primers designed using the MethPrimer program (Li and Dahiva, 2002) : 5 0 -GAA AAT ATT AAA TTA AAA TAA AAT TTA T-3 0 (forward) and 5 0 -TTT AAT TAC TAA AAA ACA AAC CAA C-3 0 (reverse). The amplicons were purified from a 2% agarose gel with QIUquick gel extraction kit (Qiagen) and sequenced. Universally Unmethylated DNA and Universally Methylated DNA (Chemicon) were used as negative and positive controls, respectively.
Cloning of the FOXO1 promoter
The proximal human FOXO1 promoter region, À1845 to À7 bp relative to the transcription start site, was amplified by PCR from genomic DNA extracted from MCF-7 cells using the following primers with overhangs to incorporate, respectively, Kpn1 and HindIII restriction sites (underlined): FOXO1pro(À7) 5 0 -GGC CGG TAC C CCT AAT TTT TCC TTT TTT CCC CTC-3 0 and FOXO1pro(À1845) 5 0 -CCG GAA GCT TGA GTG GAA GCG CGA GCC-3 0 . The PCR product was restriction digested and cloned into the Kpn1 and HindIII sites of the pGL3-basic promoter luciferase reporter vector (Promega, Madison, WI, USA) and verified by sequence analysis.
Transient and stable transfections
To assess basal FOXO1 promoter activity, HEC-1B and Ishikawa cells were plated in 96-well dishes (approximately 7000 cells/well) and transfected the following day using Lipofectamine 2000 (Invitrogen), according to the (Christian et al., 2002) using Lipofectamine2000 (Invitrogen), re-plated and incubated with 600 mg/ml G418 sulphate (Invitrogen). Individual G418-resistant colonies were isolated after 2 weeks of selection and expanded in the presence of G418 (100 mg/ml). Three clonal lines stably expressing FOXO1 were mixed to eliminate interclonal bias and used for functional analyses.
Analysis of FOXO1 mRNA stability Ishikawa and HEC-1B cells were incubated with the transcriptional inhibitor actinomycin D (Sigma-Aldrich) at a final concentration of 5 mg/ml and total mRNA extracted either immediately (designated time point 0 h) or at hourly intervals over the next 5 h. RTQ-PCR was used to determine the amount of FOXO1 mRNA, relative to the abundance of L19 transcripts, at each time point and the half-life of FOXO1 mRNA determined by calculating linear regressions to a loglinear plot of mRNA expression versus time.
Cell proliferation assay and flow cytometry Endometrial cancer cells were plated in 24-well plates (2 Â 10 3 cells/cm 2 ) for growth curve analysis. At the indicated time points, cells were trypsinized and detached from the plates, and cell number was counted under a microscopy using a hemocytometer. Each experiment was performed in quadruplicate. For MTS assay, cells were seeded onto 96-well plates, at approximately 2000 or 10 000 cells/well for proliferation and cytotoxicity assays, respectively, and allowed to attach overnight. Cell viability was determined by MTS assay using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega), according to manufacturer's instructions. To study the effects of paclitaxel on cell proliferation, cells were treated with various doses of paclitaxel for 24 h. After completion of the treatment, the percentage absorbance was calculated against untreated cells. Flow cytometry analysis was used to quantify apoptosis in endometrial cancer cells by evaluating the sub-G 1 fraction (o2n) after PI staining of ethanol-fixed cells.
Tissue specimens
The participating Local Research and Ethics Committees approved the study and patient consent was obtained before tissue collection. Snap-frozen endometrial cancer samples were obtained from patients undergoing hysterectomy without preoperative chemotherapy or radiation and histologically validated for type and grade. Normal endometrial samples were obtained from premenopausal women awaiting in vitro fertilization treatment for either tubal or male-factor infertility or at the time of laparoscopy. These samples were immersed in RNAlater (Ambion Inc, Austin, TX, USA) and stored at À801C until use.
Immunohistochemistry
Paraffin-embedded, formalin-fixed endometrial specimens were immunostained for FOXO1 and GADD45a using the Universal LSAB Plus Kits (DAKO North America, Inc., Carpinteria, CA, USA) as described previously Labied et al., 2006) , using primary antibodies against FOXO1 (Cell Signalling Technology Inc.; 1:50 dilution) and GADD45a (Santa Cruz Biotechnology Inc.; 1:100 dilution). Histological and immunohistochemical assessments were performed by two independent pathologists. Every tumour was given a score by multiplying the intensity of the staining (no staining ¼ 0; low staining ¼ 1; medium staining ¼ 2; strong staining ¼ 3) with the percent of stained epithelial cells (0% ¼ 0; under 10% ¼ 1; 1-50% ¼ 2: 51-80% ¼ 3; over 80% ¼ 4). The final immunoreactive score was graded as follows: negative, 0; low, 1-3; medium, 4-7; and high, 8-12. To validate the findings, needle core biopsies of 31 EECs were used to construct a TMA and stained for FOXO1 and GADD45a.
Methylation-specific PCR analysis Sodium bisulphite conversion of FOXO1 5 0 CpG island was performed in 3 mg of genomic DNA obtained from 17 frozen samples, 7 normal endometrial biopsies and 10 EECs. Briefly, DNA was denatured by incubation with NaOH (final concentration 0.2 M), for 10 min, at 501C and mixed with 1 mg of salmon sperm DNA (FLUKA). Freshly made sodium bisulphite solution (2.5 M sodium bisulphite (Sigma, St Louis, MO, USA), 125 mM hydroquinone (Sigma) and NaOH 2 M, pH ¼ 5.0) was added to the DNA sample to convert the unmethylated cytosines to uracils, allowing the distinction between methylated and unmethylated DNA. After 3 h incubation in the dark at 701C, converted DNA was purified, using a commercial Wizard DNA purification resin, and eluted into 45 ml of pre-heated (701C) water. Modification was completed by NaOH treatment (final concentration 0.3 M) for 10 min at room temperature, followed by neutralization of the reaction with 75 ml of 7.5 M ammonium acetate. DNA precipitation was performed, the pellet washed with 70% ethanol, the DNA dried, resuspended in 40 ml of water and stored at À201C. DNA samples were amplified by PCR. A total of 400 ng of bisulphite-modified DNA was added to the PCR mix containing Â 1 PCR buffer (16.6 mM ammonium sulphate, 67 mM Tris (pH 8.8), 6.7 mM MgCl2, and 10 mM 2-mercaptoethanol), deoxynucleotide triphosphates (each at 1 mM), 0.6 mM primers, 2% DMSO and 1unit Platinum TaqDNA polymerase (Invitrogen). Gene methylation specific primers for both methylated (FOXO1-M forward: 5 0 -GGTACGGAGAAGGGTTTTTC-3 0 , FOXO1-M reverse: 5 0 -ACGATATCTTTACTAAACGACGT-3 0 ) and unmethylated (FOXO1-U forward: 5 0 -GGTATGGAGAAGGGTTTTTTG-3 0 , FOXO1-U reverse: 5 0 -CCCACAATATCTTTACTAAA CAACATA-3 0 ) FOXO1 promoter were used to recognize and amplify FOXO1 methylated and unmethylated DNA promoter, respectively. Reactions were hot-started at 951C for 5 min and PCR amplification was carried out in a thermocycler for 38 cycles (30 s at 95 1C, 30 s at 551C, the annealing temperature, and 45 s at 721C). A final extension for 10 min at 721C was performed. Negative controls, without DNA, were performed for all PCR reactions. Each mutagenetically separated-PCR product was directly loaded into a highresolution precast 2% agarose Seakem gel (Cambrex), and stained with SYBR Gold (Invitrogen).
FOXO1 and endometrial cancer T Goto et al
Statistical analysis
All values are presented as mean7s.d. where appropriate. Statistical significance between two groups was determined by use of a two-tailed t-test, and values of Po0.05 were considered significant.
Abbreviations
EEC, endometrioid endometrial cancer; PI3K, phosphatidylinositol-3-kinase; 5-aza-dC, 5-aza-2 0 -deoxycytidine; GADD45a, growth arrest-and DNA damage-inducible protein a of 45 kDa; MSP, methylation-specific PCR; TMA, tissue microarray.
